Atomoxetine

Atomoxetine (CAS 83015-26-3) is a selective norepinephrine reuptake inhibitor active pharmaceutical ingredient used in the manufacture of prescription medications. Atomoxetine hydrochloride is the commercially predominant salt form and the name most commonly referenced in regulatory filings and procurement.

It is sourced by pharmaceutical manufacturers and contract development organizations as a finished API for solid dosage form production. The primary application is in the manufacture of oral capsule formulations targeting attention deficit hyperactivity disorder, where it functions as the sole active ingredient.

Contract manufacturers and generic drug producers source this API to develop bioequivalent products against established reference listed drugs. Specialty pharmaceutical companies also use it in reformulation projects targeting modified-release or pediatric-appropriate dosage forms.

Regulatory starting material suppliers and API intermediates producers may handle earlier synthetic precursors for use in validated synthesis routes. Atomoxetine is available as a white to off-white crystalline powder, supplied as either the free base or the hydrochloride salt.

Standard grades conform to ICH Q7 GMP requirements, with material typically characterized against USP or in-house reference standards. Packaging is offered in quantities ranging from research-scale grams to multi-kilogram commercial batches.